| Literature DB >> 32575706 |
Anna Winiarska-Mieczan1, Tomasz Mieczan2, Grzegorz Wójcik3.
Abstract
Psoriasis is a common, chronic, hyperproliferative, inflammatory skin disease occurring in most ethnic groups in the world. The disease is hereditary but the process of its inheritance is complex and still not fully understood. At the same time, it has been observed that psoriatic lesions may be triggered by certain prooxidative external factors: using narcotics, smoking, drinking alcohol, physical and mental stress, as well as bacterial infections and injury. Since the main physiological marker of psoriasis relates to disorders in the organism's antioxidative system, it is necessary to develop a well-balanced combination of pharmaceuticals and dietary antioxidants to facilitate the effective treatment and/or prevention of the disease. The dietary sources of antioxidants must be adequate for chronic use regardless of the patient's age and be easily available, e.g., as ingredients of regular food or dietary supplements. Diet manipulation is a promising therapeutic approach in the context of modulating the incidence of chronic diseases. Another potentially viable method entails the use of nutrigenomics, which guarantees a multiaspectual approach to the problem, including, in particular, analyses of the genetic profiles of psoriasis patients with the view to more accurately targeting key problems. The present paper pertains to the significance of redox equilibrium in the context of psoriasis. Based on information published in worldwide literature over the last decade, the impact of dietary exogenous antioxidants on the course of this chronic disease was analysed.Entities:
Keywords: diet; exogenous antioxidants; perspectives; prevention; psoriasis
Mesh:
Substances:
Year: 2020 PMID: 32575706 PMCID: PMC7353401 DOI: 10.3390/nu12061841
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Plasma antioxidant capacity and lipid peroxidation biomarkers in psoriasis.
| Characteristic | Antioxidant Capacity | Lipid Levels | Peroxidation Biomarkers | References |
|---|---|---|---|---|
| Psoriasis | ≈ SOD | ↑ MDA | [ | |
| Psoriasis | ↓ SOD; ↓ CAT; ↑ NO; ↓ TAS | ↑ MDA | [ | |
| Psoriasis | ↓ vitamin E; ↓ CAT | ↑ MDA | [ | |
| Psoriasis | ↓ SOD; ↓ GPX | ↑ MDA | [ | |
| Psoriasis | ↑ TG; ↑ TC | ↑ MDA | [ | |
| Psoriasis | ↑ NOX; ↑ ROS; ↓ CAT; ↓ GSH; ↓ vitamin E; ↓ GPX | ↑ MDA | [ | |
| Psoriasis | ↓ SOD; ↓ vitamin E; ↓ vitamin A; ↓ Zn; ↓ Cu | ↑ MDA | [ | |
| Psoriasis | ≈ native SH; ≈ total SH; ↑ SS; ≈ SS/total SH | [ | ||
| Psoriasis | ≈ native SH; ↓ total SH; ≈ SS; ↑ SS/total SH | [ | ||
| Psoriasis | ≈ native SH; ≈ total SH; ↑ SS; ↓ SS/total SH | ↑ TC; ↑ TG; ≈ HDL-chol; ≈ LDL-chol | [ | |
| Psoriasis | ↓ G6PDH | ↑ ESP | [ | |
| Psoriasis | ↓ SOD; ↓ CAT | ↑ TC; ↑ LDL-chol; ↓ HDL-chol; ↑ ApoB; ↑ Lp(a); ↑ TG | ↑ MDA; ↓ PON | [ |
| Psoriasis | ↓ HDL-chol; ≈ LDL-chol; ≈ TG; ≈ TC; ↓ ox-LDL | [ | ||
| Psoriasis | ↓ RGSH | ↓ HDL-chol; ≈ LDL-chol; ↑ TG; ↑ TC; ↑ ox-LDL; | ↑ MDA | [ |
| Psoriasis | ↑ MDA | [ | ||
| Psoriasis | ↓ SOD; ↑ CAT | ↑ MDA | [ | |
| Psoriasis | ↓ GPX; ≈ CAT; ≈ SOD | ↑ TG; ↑ TC; ↑ LDH-chol; ≈ HDL-chol | ↑ MDA | [ |
| Psoriasis | ↓ SOD; ↓ GPX | ↑ MDA | [ | |
| Psoriasis | ↑ TG; ↑ TC; ↑ LDH-chol; ↑ VLDL-chol; ≈ HDL-chol | ↑ MDA | [ | |
| Psoriasis | ↑ NO | ↑ MDA | [ | |
| Psoriasis | ↓ SOD; ↓ GPX | ↑ TG; ↑ TC; ↑ LDH-chol; ↓ HDL-chol; ↑ VLDL-chol | ↑ MDA | [ |
↑—Increased concentration or activity in comparison to the control (healthy) group; ↓—decreased or inhibited concentration or activity in comparison to the control (healthy) group; ≈ no differences in comparison to the control (healthy) group; SS—disulfides; SH—thiol; TC—total cholesterol; HDL-chol—high-density lipoprotein cholesterol; LDL-chol—low-density lipoprotein cholesterol; VLDL-chol—very low-density lipoprotein; G6PDH—glucose-6-phosphate dehydrogenase; ESP—lipid peroxidation of erythrocytes; GSH—glutathione; SOD—superoxide dismutase; CAT—catalase; MDA—malondialdehyde; GPX—glutathione peroxidase; TG—triglycerides; ox-LDL—oxidised LDL; ApoB—apolipoprotein B; PON—paraoxonase; Lp(a)—lipoprotein(a); NO—nitric oxide; TAS—total antioxidant status; RGSH—reduced glutathione; NOX—NADPH oxidase; ROS—reactive oxygen species.
Protective effects of dietary antioxidants on the antioxidative status in patients with psoriasis.
| Antioxidant/Design | Duration of Therapy | Characteristic | Target Sites | Antioxidant Capacity | References |
|---|---|---|---|---|---|
| Tablet containing 100 μg selenium + 1500 IU vitamin A + 90 mg vitamin C + 30 mg vitamin E; once daily | 4 weeks | Seven psoriatic patients, different severities | Plasma, erythrocytes | ≈ MDA; ≈ CAT; ≈ SOD | [ |
| Epigallocatechin-3-gallate EGCG glycerin solvent (3%, 30 mg/mL, glycerin solvent: 50% glycerin, 50% normal saline) | 3 weeks | Imiquimod induced psoriasis-like BALB/c mice | Serum | ↑ SOD; ↑ CAT; ↓ MDA | [ |
| 30 mg β-carotene + 27.5 mg zinc sulfate monohydrate + 0.2 mg monohydrated selenium dioxide + 2 mg manganese + 1 mg copper | 8 weeks | 33 patients, 20–60 years, chronic plaque psoriasis | Serum | ↓ MDA; ↑ TAC | [ |
| 50 mg/d coenzyme Q10 (ubiquinone acetate) + 50 mg/d vitamin E (natural alpha-tocopherol) + 48 µg/d selenium (aspartate salt) dissolved in soy lecithin | 30–35 days | 58 patients, severe erythrodermic and arthropathic forms of psoriasis | Granulocytes, affected epidermis | ↑ SOD; ↑ CAT | [ |
| 12 weeks | 60 patients, 3 groups: Group 1 (control)—methotrexate tablets; Group 2— | Serum | ↓ MDA | [ |
↑—Increased concentration or activity in comparison to the control (untreated) group; ↓—decreased or inhibited concentration or activity in comparison to the control (untreated) group; ≈ no differences in comparison to the control (untreated) group; TAC—total antioxidant capacity; MDA—malondialdehyde; SOD—superoxide dismutase; CAT—catalase.
Figure 1Oxidative stress in psoriasis—causes or consequences of the disease.
Figure 2The effects of dietary supplementation with antioxidants in patients with psoriasis. Legends: ROS—reactive oxygen species; SOD—superoxide dismutase; CAT–catalase; GPX—glutathione peroxidase; GSH–glutathione; NF-κB—nuclear factor kappa B; IL–interleukins; TNF—tumour necrosis factor; IFN-α—alpha interferon; Nrf2—nuclear factor erythroid 2-related factor 2.